Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by G. R. Ott
CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase With Antitumor Activity in Experimental Models of Human Cancers
Molecular Cancer Therapeutics
Cancer Research
Oncology
Related publications
TAS0728, a Covalent-Binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
Molecular Cancer Therapeutics
Cancer Research
Oncology
Antitumor Activity of MLN8054, an Orally Active Small-Molecule Inhibitor of Aurora a Kinase
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
TAS4464, a Highly Potent and Selective Inhibitor of NEDD8 Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models
Molecular Cancer Therapeutics
Cancer Research
Oncology
Rogaratinib: A Potent and Selective Pan-FGFR Inhibitor With Broad Antitumor Activity in FGFR-overexpressing Preclinical Cancer Models
International Journal of Cancer
Cancer Research
Oncology
GSK1070916, a Potent Aurora B/C Kinase Inhibitor With Broad Antitumor Activity in Tissue Culture Cells and Human Tumor Xenograft Models
Molecular Cancer Therapeutics
Cancer Research
Oncology
BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers
Molecular Cancer Therapeutics
Cancer Research
Oncology
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF
Cancer Research
Cancer Research
Oncology
Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase With Potent Antimelanoma Activity
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Abstract P6-20-02: Activity of Larotrectinib, a Highly Selective Inhibitor of Tropomyosin Receptor Kinase, in TRK Fusion Breast Cancers
